Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss and Updates Strategy
Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Research and development expenses declined 83% to $1.1 million. The company has $30.6 million in cash and is exploring new research opportunities, including a neurotechnology device for sleep-related conditions. Proceeds from a private placement will fund working capital and R&D.
